State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of 879,862 shares of Rigel Pharmaceuticals Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 879,862 shares of Rigel Pharmaceuticals Inc. common stock.
  • Percent of class: The 879,862 shares represent 4.7% of the class, according to the filing.
  • Shared voting power: State Street disclosed shared power to vote or direct the vote for 858,066 shares, with sole voting power of 0.
  • Shared dispositive power: The filing reports shared power to dispose or direct the disposition of 879,862 shares, with sole dispositive power of 0.
  • Subsidiaries involved: The filing identifies SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, and State Street Global Advisors Trust Company as the relevant subsidiaries through which the securities were acquired.
  • Triggering event date: The date of the event requiring the filing is listed as September 30, 2026.

State Street Corporation's Schedule 13G Filing on Rigel Pharmaceuticals

State Street Corporation, a holding company incorporated in Massachusetts and headquartered at One Congress Street, Suite 1, Boston, MA 02114, filed a Schedule 13G disclosing its beneficial ownership position in Rigel Pharmaceuticals Inc. (CUSIP: 766559702). Rigel Pharmaceuticals is headquartered at 611 Gateway Blvd, Suite 900, South San Francisco, California 94080, according to the filing.

According to the filing, State Street Corporation is classified as a parent holding company or control person (Type: HC). The statement was signed by Alok Maheshwary, Senior Vice President, on November 9, 2026. Three subsidiaries are identified in connection with the reported holdings: SSGA Funds Management, Inc. (investment adviser), State Street Global Advisors Europe Limited (investment adviser), and State Street Global Advisors Trust Company (investment adviser).

The filing states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." Item 5 of the filing notes ownership of 5 percent or less of a class, consistent with the reported 4.7% figure. Item 6 is marked "NOT APPLICABLE," indicating no other person is known to have the right to receive or direct dividends or sale proceeds for more than 5% of the class.

What Was Disclosed

State Street Corporation disclosed a 4.7% beneficial ownership stake, totaling 879,862 shares, in Rigel Pharmaceuticals Inc. common stock as of September 30, 2026, with the position held through three investment adviser subsidiaries in the ordinary course of business.